FL118

Synonyms: 10,11-(Methylenedioxy)-20(S)-camptothecin
FL118 (10,11-(Methylenedioxy)-20(S)-camptothecin) 是一种喜树碱 (Camptothecin; MS-H65088) 类似物,也是一种口服有效的 survivin 抑制剂,可与 DDX5 (p68) 结合并使其去磷酸化、降解,因此可用于癌症研究。
产品编号: MS-X59712 纯度: 99.22% CAS No.: 135415-73-5 分子式: C21H16N2O6 分子量: 392.36
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

FL118 (10,11-(Methylenedioxy)-20(S)-camptothecin) 是一种喜树碱 (Camptothecin; MS-H65088) 类似物,也是一种口服有效的 survivin 抑制剂,可与 DDX5 (p68) 结合并使其去磷酸化、降解,因此可用于癌症研究。

生物实验数据

生物活性 FL118 (10,11-(Methylenedioxy)-20(S)-camptothecin), a camptothecin (Camptothecin; MS-H65088) analog, is an orally active survivin inhibitor that binds to DDX5 (p68), inducing its dephosphorylation and degradation, and can be used for cancer research.
体外研究
(In Vitro)

FL118 (0-200 nM; 24, 48 and 72 h ) inhibits the cell proliferation of ES-2 and SK-O-V3 cells.
FL118 (0-100 nM; 0 and 24 h) inhibits the migration of ES-2 and SK-O-V3 cells.
FL118 (0-100 nM; 48 h) affects the expression level of cytoglobin (CYGB).
FL118 (10 and 100 nM; 48 h) inhibits PI3K/AKT/mTOR signaling pathway, and affects the expression level of vimentin and E-cadherin in ovarian cancer cells.
FL118 (0-100 nM; 6 and 24 h) dephosphorylates and degrades DDX5.
FL118 (0-500 nM; 24, 48, 72 h) regulates survivin, McL-1, XIAP, cIAP2, c-MYc and mKras by regulating DDX5.
FL118 (0-1 μM, 24 h) shows significant cytotoxic activity against the three tumor cell lines (A549, MDA-MB-231, and RM-1 cells).
FL118 (0-10 nM, 48 h) increases the production of PARP cleavage, and induces apoptosis in A549.
FL118 (0-10 nM, 48 h) arrests A549 cells mainly at the G2/M phase.

Western Blot Analysis

Cell Line: ES-2 and SK-O-V3 cell lines
Concentration: 10 and 100 nM
Incubation Time: 48 h
Result: Effectively inhibited the activation of PI3K/AKT/mTOR signaling pathway in ovarian cancer cells and also inhibited the migration of ES-2 and SK-O-V3 cells.

Cell Migration Assay

Cell Line: ES-2 and SK-O-V3 cell lines
Concentration: 0, 10 and 100 nM
Incubation Time: 0 and 24 h
Result: Inhibited the migration of ES-2 and SK-O-V3 cells dose-dependenly.

RT-PCR

Cell Line: ES-2 and SK-O-V3 cell lines
Concentration: 0, 10 and 100 nM
Incubation Time: 48 h
Result: Promoted CYGB expression.

Cell Proliferation Assay

Cell Line: ES-2 and SK-O-V3 cell lines
Concentration: 0, 1, 10, 50, 100 and 200 nM
Incubation Time: 24, 48 and 72 h
Result: Inhibited the cell proliferation of ES-2 and SK-O-V3 cells time- and dose-dependently.

Western Blot Analysis

Cell Line: SW620 and Mia Paca-2
Concentration: 0, 10 and 100 nM
Incubation Time: 6 and 24 h
Result: Induced dephosphorylation of DDX5 through the ubiquitin-proteasome degradation pathway and degraded DDX5 time-dependently.

Western Blot Analysis

Cell Line: PDAC Panc1, CRC HCT-8, SW620, Mia Paca-2, Panc-1, HCT-8 cell lines
Concentration: 0, 10, 100 and 500 nM
Incubation Time: 24, 48, 72 h
Result: Controled the expression of survivin, Mcl-1, XIAP, cIAP2, c-Myc and mKras by regulated DDX5, as an upstream master regulator in cancer development and malignant networks.

Cell Cytotoxicity Assay

Cell Line: A549, MDA-MB-231, RM-1
Concentration: 0-1 μM
Incubation Time: 24 h
Result: Showed cytotoxicity in A-549 (human lung carcinoma), MDA-MB-231 (human breast carcinoma) and RM-1 (mouse prostate carcinoma), with IC50 values of 8.94 ± 1.54, 24.73 ± 13.82, and 69.19 ± 8.34 nM, respectively.

Apoptosis Analysis

Cell Line: A549 cells
Concentration: 0, 2.5, 5, 10 nM
Incubation Time: 48 h
Result: Resulted in the downregulation of survivin. Increased the production of PARP cleavage in a concentration-dependent manner, which is the hallmark of apoptosis. Induced apoptosis in A549.

Cell Cycle Analysis

Cell Line: A549 cells
Concentration: 0, 2.5, 5, 10 nM
Incubation Time: 48 h
Result: Increased G2/M cell population in a concentration-dependent manner, and arrested A549 cells mainly at the G2/M phase.
体内研究
(In Vivo)

FL118 (5 and 10 mg/kg; p.o. once a week for 20 days) inhibits antitumor activity.
FL118 (0-1.5 mg/kg, i.p. once every other day for five times) effectively eliminates human colon and head-and-neck tumors that acquire irinotecan or topotecan resistance.
FL118 (1.5 mg/kg, i.v. once) exhibits favorable pharmacokinetics profiles.
Pharmacokinetic Parameters of FL118 in female SCID mice.

Sample FaDu SW620 Plasma
T1/2 (hr) 6.852 12.75 1.788
Tmax (hr) 0.167 0.167 0.167
Cmax (ng/g, mL) 115 158 43
AUC (hr*ng/g) 413 842 82
AUC∞ (hr*ng/g) 448 897 104
AUC% Extrap (%) 7.74 6.17 21.7
Vz (g/kg) (ml/kg) 33052 30742 36849
Cl (g/hr/kg) (ml/hr/kg) 3343 1671 14287

Animal Model: Fmale BALB/c nude mice
Dosage: 5 and 10 mg/kg
Administration: Oral gavage; 5 mg/kg for once a week; 10 mg/kg for once a week; for 20 days
Result: Showed better antitumor activity than topotecan and dose-dependenly suppressed the growth of ES-2 tumors by upregulating the expression level of CYGB.
Animal Model: SCID (severe combined immunodeficiency) mice bearing human SW620 (colon) and FaDu (head-and-neck) xenograft tumors (ten-week-old, female, 20-25 g, 5 mice per cage)
Dosage: 0, 0.75, 1, 1.5 mg/kg
Administration: IP, once every other day for five times as one cycle (If tumors relapse, mice were treated with FL118 for second or third cycles)
Result: Eliminated human xenograft tumors that acquired irinotecan or topotecan resistance, and was also effective after multiple cycles of treatment without the generation of FL118 resistance.
Animal Model: SCID (severe combined immunodeficiency) mice bearing human SW620 (colon) and FaDu SCID mice bearing human SW620 (colon) and FaDu (head-and-neck) xenograft tumors (ten-week-old, female, 20-25 g, 5 mice per cage)
Dosage: 1.5 mg/kg
Administration: IV, once
Result: Exhibited favorable pharmacokinetics profiles.
性状 固体
颜色 Light brown to brown

化学信息

分子量 392.36
分子式 C21H16N2O6
CAS No. 135415-73-5
别名 10,11-(Methylenedioxy)-20(S)-camptothecin

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 0.13 mg/mL (0.33 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 1 mg/mL (2.55 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.5487 mL12.7434 mL25.4868 mL63.7170 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础